Mutually exclusive recurrent KRAS and MAP2K1 mutations in Rosai–Dorfman disease

Rosai–Dorfman disease is a histiocytic disorder with a poorly defined pathogenesis. Recent molecular studies have revealed recurrent mutations involving genes in the MAPK/ERK pathway in Langerhans cell histiocytosis and Erdheim–Chester disease. However, cases of Rosai–Dorfman disease have rarely been assessed. We performed next-generation sequencing to assess 134 genes on 21 cases of Rosai–Dorfman disease, including 13 women and 8 men with a median age of 43 years (range, 3–82). In all, 13 had extranodal, 5 had nodal, and 3 had coexistent nodal and extranodal disease. The head and neck region was the most common area involved (n=7). Mutation analysis detected point mutations in 7 (33%) cases, including KRAS (n=4) and MAP2K1 (n=3). No mutations were identified in ARAF, BRAF, PIK3CA, or any other genes assessed. Immunohistochemistry demonstrated p-ERK overexpression in 3 cases, all harboring MAP2K1 mutations. Patients carrying mutated genes were younger (median age, 10 vs 53 years, P=0.0347) with more pediatric patients (4/7 vs 1/14, P=0.0251). The presence of mutations correlated with location being more common in the head and neck region; 6/7 (86%) mutated vs 1/14 (7%) unmutated cases (P=0.0009). All 5 (100%) mutated cases with available staging information had a multifocal presentation, whereas only 3/11 (27%) unmutated patients had multifocal disease (P=0.0256). Treatment information was available in 10 patients, including radical resection (n=4), resection and radiation (n=3), and cladribine-based chemotherapy (n=3). With a median follow-up of 84 months (range, 7–352), 7 remained in clinical remission and 3 had persistent disease. No correlation between mutation status and clinical outcome was noted. In summary, we detected mutually exclusive KRAS and MAP2K1 mutations in one-third of cases of Rosai–Dorfman disease suggesting this subgroup are clonal and involve activation of MAPK/ERK pathway. Our data contribute to the understanding of the biology of Rosai–Dorfman disease and point to potential diagnostic and therapeutic targets.

[1]  J. G. Humble,et al.  Biological Interaction Between Lymphocytes and. Other Cells , 1956, British journal of haematology.

[2]  P. Destombes.  [Adenitis with lipid excess, in children or young adults, seen in the Antilles and in Mali. (4 cases)]. , 1965, Bulletin de la Societe de pathologie exotique et de ses filiales.

[3]  J. Rosai,et al.  Sinus histiocytosis with massive lymphadenopathy. A newly recognized benign clinicopathological entity. , 1969, Archives of pathology.

[4]  J. Rosai,et al.  Sinus histiocytosis with massive lymphadenopathy: A pseudolymphomatous benign disorder.Analysis of 34 cases , 1972, Cancer.

[5]  J. Rosai,et al.  Sinus histiocytosis with massive lymphadenopathy. An analysis of 14 deaths occurring in a patient registry , 1984, Cancer.

[6]  J. Rosai,et al.  Immunologic abnormalities and their significance in sinus histiocytosis with massive lymphadenopathy. , 1984, American journal of clinical pathology.

[7]  J. Rosai,et al.  Sinus histiocytosis with massive lymphadenopathy (Rosai-Dorfman disease): review of the entity. , 1990, Seminars in diagnostic pathology.

[8]  E. Jaffe,et al.  Detection of human herpesvirus 6 in tissues involved by sinus histiocytosis with massive lymphadenopathy (Rosai-Dorfman disease). , 1992, The Journal of infectious diseases.

[9]  J. Chan,et al.  The Rosai–Dorfman disease histiocytes are not infected by Epstein–Barr virus , 1994, Histopathology.

[10]  M. Cobb,et al.  Mitogen-activated protein kinase pathways. , 1997, Current opinion in cell biology.

[11]  R. Marasca,et al.  Expression of human herpesvirus-6 antigens in benign and malignant lymphoproliferative diseases. , 1998, The American journal of pathology.

[12]  J. Rosai,et al.  The digestive system manifestations of Rosai-Dorfman disease (sinus histiocytosis with massive lymphadenopathy): review of 11 cases. , 2000, Human pathology.

[13]  Brad J. Davis,et al.  Rosai-Dorfman Disease Isolated to the Central Nervous System: A Report of 11 Cases , 2001, Modern Pathology.

[14]  W. Kolch.  Coordinating ERK/MAPK signalling through scaffolds and inhibitors , 2005, Nature Reviews Molecular Cell Biology.

[15]  K. Ganapathy,et al.  Rosai–Dorfman disease of the central nervous system , 2005, Journal of Clinical Neuroscience.

[16]  L. Füzesi,et al.  Parvovirus B19 detected in Rosai–Dorfman disease in nodal and extranodal manifestations , 2006, Journal of Clinical Pathology.

[17]  N. Brousse,et al.  Dramatic clinical efficacy of cladribine in Rosai-Dorfman disease and evolution of the cytokine profile: towards a new therapeutic approach. , 2006, Haematologica.

[18]  J. Sugar,et al.  Atypical Ocular Presentations of Rosai-Dorfman Disease , 2008, Ocular immunology and inflammation.

[19]  J. Settleman,et al.  Targeting the RAF-MEK-ERK pathway in cancer therapy. , 2009, Cancer letters.

[20]  L. Rybak,et al.  Primary Rosai-Dorfman Disease of Bone: A Clinicopathologic Study of 15 Cases , 2010, The American journal of surgical pathology.

[21]  W. Hahn,et al.  Recurrent BRAF mutations in Langerhans cell histiocytosis. , 2010, Blood.

[22]  M. Fleming,et al.  Endogenous oncogenic Nras mutation promotes aberrant GM-CSF signaling in granulocytic/monocytic precursors in a murine model of chronic myelomonocytic leukemia. , 2010, Blood.

[23]  M. Copin,et al.  High prevalence of BRAF V600E mutations in Erdheim-Chester disease but not in other non-Langerhans cell histiocytoses. , 2012, Blood.

[24]  A. Stenzinger,et al.  BRAFV600E mutant protein is expressed in cells of variable maturation in Langerhans cell histiocytosis. , 2012, Blood.

[25]  Dongfang Li,et al.  Genome sequencing of 161 Mycobacterium tuberculosis isolates from China identifies genes and intergenic regions associated with drug resistance , 2013, Nature Genetics.

[26]  P. Cluzel,et al.  Dramatic efficacy of vemurafenib in both multisystemic and refractory Erdheim-Chester disease and Langerhans cell histiocytosis harboring the BRAF V600E mutation. , 2013, Blood.

[27]  A. Salajegheh,et al.  B-Raf mutation: a key player in molecular biology of cancer. , 2013, Experimental and molecular pathology.

[28]  Heather L. Mulder,et al.  Whole-genome sequencing identifies genetic alterations in pediatric low-grade gliomas , 2013, Nature Genetics.

[29]  K. Aldape,et al.  Frequency and spectrum of BRAF mutations in a retrospective, single-institution study of 1112 cases of melanoma. , 2013, The Journal of molecular diagnostics : JMD.

[30]  T. Garrington,et al.  Clofarabine salvage therapy in refractory multifocal histiocytic disorders, including Langerhans cell histiocytosis, juvenile xanthogranuloma and Rosai–Dorfman disease , 2014, Pediatric blood & cancer.

[31]  F. Stingo,et al.  BRAF kinase domain mutations are present in a subset of chronic myelomonocytic leukemia with wild‐type RAS , 2014, American journal of hematology.

[32]  Paul S. Meltzer,et al.  High prevalence of MAP2K1 mutations in variant and IGHV4-34 expressing hairy-cell leukemia , 2013, Nature Genetics.

[33]  D. Muzny,et al.  Mutually exclusive recurrent somatic mutations in MAP2K1 and BRAF support a central role for ERK activation in LCH pathogenesis. , 2014, Blood.

[34]  O. Abdel-Wahab,et al.  Recurrent RAS and PIK3CA mutations in Erdheim-Chester disease. , 2014, Blood.

[35]  H. Cha,et al.  Frequent detection of BRAFV600E mutations in histiocytic and dendritic cell neoplasms , 2014, Histopathology.

[36]  J. Ryu,et al.  BRAF V600E Expression in Langerhans Cell Histiocytosis: Clinical and Immunohistochemical Study on 25 Pulmonary and 54 Extrapulmonary Cases , 2014, American Journal of Surgical Pathology.

[37]  L. Sokol,et al.  Rosai-Dorfman disease: tumor biology, clinical features, pathology, and treatment. , 2014, Cancer control : journal of the Moffitt Cancer Center.

[38]  S. Romano,et al.  Rosai-Dorfman disease: a report of eight cases in a tertiary care center and a review of the literature. , 2014, Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas.

[39]  E. Jaffe,et al.  A subset of Rosai–Dorfman disease cases show increased IgG4‐positive plasma cells: another red herring or a true association with IgG4‐related disease? , 2014, Histopathology.

[40]  P. Grenier,et al.  Reproducible and sustained efficacy of targeted therapy with vemurafenib in patients with BRAF(V600E)-mutated Erdheim-Chester disease. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[41]  N. Radosevic-Robin,et al.  Common cancer-associated PIK3CA activating mutations rarely occur in Langerhans cell histiocytosis. , 2015, Blood.

[42]  J. Palazzo,et al.  Disseminated histiocytoses: Biomarkers beyond BRAFV600E. , 2015 .

[43]  J. Blay,et al.  Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations. , 2015, The New England journal of medicine.

[44]  M. Merad,et al.  BRAF-V600E expression in precursor versus differentiated dendritic cells defines clinically distinct LCH risk groups , 2015, The Journal of experimental medicine.

[45]  B. Falini,et al.  BRAF V600E mutation in hairy cell leukemia: from bench to bedside. , 2016, Blood.

[46]  D. Wheeler,et al.  Alternative genetic mechanisms of BRAF activation in Langerhans cell histiocytosis. , 2016, Blood.

[47]  B. Taylor,et al.  Diverse and Targetable Kinase Alterations Drive Histiocytic Neoplasms. , 2016, Cancer discovery.

[48]  M. Kluk,et al.  Rosai–Dorfman Disease Harboring an Activating KRAS K117N Missense Mutation , 2016, Head and Neck Pathology.

[49]  R. Cason,et al.  BRAF and MAP2K1 mutations in Langerhans cell histiocytosis: a study of 50 cases. , 2016, Human pathology.

[50]  A. Fischer,et al.  Revised Classification of Histiocytoses and Neoplasms of the Macrophage-dendritic Cell Lineages Histiocyte and Dendritic Cell Lineages the " L " (langerhans) Group , 2022 .

[51]  D. Sado,et al.  Rosai-Dorfman disease and the heart. , 2016, Intractable & rare diseases research.

[52]  K. Ohshima,et al.  BRAFV600E and MAP2K1 mutations in Langerhans cell histiocytosis occur predominantly in children , 2017, Hematological oncology.

[53]  R. Cason,et al.  Langerhans cell histiocytosis associated with lymphoma: an incidental finding that is not associated with BRAF or MAP2K1 mutations , 2017, Modern Pathology.